177Lu-PSMA-617联合Idronoxil治疗终末期转移性去势抵抗性前列腺癌:I/II期试验患者结局与疗效预测因素
本研究为I/II期试验,56例经紫杉类化疗和新型雄激素信号抑制剂治疗的进展性mCRPC患者接受177Lu-PSMA-617(7.5 GBq)联合放射增敏剂idronoxil(NOX66)治疗。联合方案安全可行,86%患者PSA下降,61%患者PSA下降≥50%,中位PSA无进展生存7.5个月,中位总生存19.7个月。PSMA SUVmean较高与治疗反应相关,而PSMA肿瘤体积较高和ASI治疗不足12个月与总生存较差相关。
要点
- 177Lu-PSMA-617联合NOX66在经多线治疗的mCRPC中安全可行,常见不良事件为贫血、乏力和口干。
- 86%患者PSA下降,61%患者PSA下降≥50%,中位PSA-PFS为7.5个月,中位OS为19.7个月。
- PSMA SUVmean、PSMA阳性肿瘤体积和ASI治疗持续时间与结局独立相关。
核心结论
- NOX66联合177Lu-PSMA-617是mCRPC三线及以上治疗的安全可行策略。
- PSMA SUVmean、PSMA阳性肿瘤体积和ASI治疗持续时间与结局独立相关。
研究设计与样本
- I/II期试验纳入56例经紫杉类化疗和新型雄激素信号抑制剂治疗的进展性mCRPC患者。
- 患者接受最多6个周期177Lu-PSMA-617(7.5 GBq,第1天)联合NOX66栓剂(第1-10天),每6周为一周期。
- NOX66剂量分为400 mg(队列1,n=8)、800 mg(队列2,n=24)和1,200 mg(队列3,n=24)。
- 基线行68Ga-PSMA和18F-FDG PET/CT及血液生物标志物分析,主要终点为安全性和耐受性。
主要发现
- 中位PSA无进展生存期为7.5个月(95% CI,5.9-9个月),中位总生存期为19.7个月(95% CI,9.5-30个月)。
- 常见不良事件为贫血、乏力和口干,NOX66相关肛门刺激发生率为38%。
- 较高的PSMA SUVmean与治疗反应相关,较高的PSMA肿瘤体积和ASI治疗不足12个月与总生存较差相关。
关键数值与推荐
- 100例筛查者中56例(56%)入组,PET影像标准筛查失败率为26%(26/100)。
- 所有患者既往接受过ASI和多西他赛治疗,95%(53/56)接受过卡巴他赛。
临床怎么用
- 对于经紫杉类化疗和ASI治疗后的进展性mCRPC患者,可考虑177Lu-PSMA-617联合NOX66治疗。
- 基线PSMA SUVmean较高、PSMA肿瘤体积较低及ASI治疗持续时间较长者可能从联合治疗中更多获益。
局限性
- 本研究为I/II期单臂试验,样本量有限(56例),无对照组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
177Lu-PSMA-617 is an effective therapy for metastatic castration-resistant prostate cancer (mCRPC). However, treatment resistance occurs frequently, and combination therapies may improve outcomes. We report the final safety and efficacy results of a phase I/II study combining 177Lu-PSMA-617 with idronoxil (NOX66), a radiosensitizer, and examine potential clinical, blood-based, and imaging biomarkers. Methods: Fifty-six men with progressive mCRPC previously treated with taxane chemotherapy and novel androgen signaling inhibitor (ASI) were enrolled. Patients received up to 6 doses of 177Lu-PSMA-617 (7.5 GBq) on day 1 in combination with a NOX66 suppository on days 1-10 of each 6-wk cycle. Cohort 1 (n = 8) received 400 mg of NOX66, cohort 2 (n = 24) received 800 mg, and cohort 3 (n = 24) received 1,200 mg. 68Ga-PSMA and 18F-FDG PET/CT were performed at study entry, and semiquantitative imaging analysis was undertaken. Blood samples were collected for analysis of blood-based biomarkers, including androgen receptor splice variant 7 expression. The primary outcomes were safety and tolerability; secondary outcomes included efficacy, pain scores, and xerostomia. Regression analyses were performed to explore the prognostic value of baseline clinical, blood-based, and imaging parameters. Results: Fifty-six of the 100 men screened were enrolled (56%), with a screening failure rate of 26% (26/100) for PET imaging criteria. All men had received prior treatment with ASI and docetaxel, and 95% (53/56) had received cabazitaxel. Ninety-six percent (54/56) of patients received at least 2 cycles of combination NOX66 and 177Lu-PSMA-617, and 46% (26/56) completed 6 cycles. Common adverse events were anemia, fatigue, and xerostomia. Anal irritation attributable to NOX66 occurred in 38%. Forty-eight of 56 had a reduction in prostate-specific antigen (PSA) level (86%; 95% CI, 74%-94%); 34 of 56 (61%; 95% CI, 47%-74%) had a PSA reduction of at least 50%. Median PSA progression-free survival was 7.5 mo (95% CI, 5.9-9 mo), and median overall survival was 19.7 mo (95% CI, 9.5-30 mo). A higher PSMA SUVmean correlated with treatment response, whereas a higher PSMA tumor volume and prior treatment with ASI for less than 12 mo were associated with worse overall survival. Conclusion: NOX66 with 177Lu-PSMA-617 is a safe and feasible strategy in men being treated with third-line therapy and beyond for mCRPC. PSMA SUVmean, PSMA-avid tumor volume, and duration of treatment with ASI were independently associated with outcome.
引用
- Pathmanandavel S, Crumbaker M, Yam AO, et al. 177Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II Trial. J Nucl Med. 2021. PMID: 34326127. doi:10.2967/jnumed.121.262552
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。